Curt Balch

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. doi Epigenetic targeting therapies to overcome chemotherapy resistance
    Curt Balch
    Medical Sciences, Indiana University School of Medicine, Indiana University School of Medicine, Jordan Hall 300, 1001 East Third Street, Bloomington, IN 47405, USA
    Adv Exp Med Biol 754:285-311. 2013
  2. pmc A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells
    Curt Balch
    Medical Sciences Program, Indiana University, Bloomington, IN, USA
    Cancer Biol Ther 13:681-93. 2012
  3. pmc An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules
    Huaxia Qin
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    BMC Syst Biol 3:73. 2009
  4. pmc A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer
    Fang Fang
    Medical Sciences Program, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Cancer 116:4043-53. 2010
  5. pmc Enriched transcription factor binding sites in hypermethylated gene promoters in drug resistant cancer cells
    Meng Li
    Medical Sciences, School of Medicine, Indiana University, Bloomington, IN 47404, USA
    Bioinformatics 24:1745-8. 2008
  6. pmc Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance
    Fuxiao Xin
    School of Informatics, Indiana University, Bloomington, IN 47405, USA
    Bioinformatics 25:430-4. 2009
  7. doi Methyl group acceptance assay for the determination of global DNA methylation levels
    Kenneth P Nephew
    Department of Cellular and Integrative Physiology, Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN, USA
    Methods Mol Biol 507:35-41. 2009
  8. pmc Minireview: epigenetic changes in ovarian cancer
    Curt Balch
    Medical Sciences, Indiana University School of Medicine, Bloomington, Indiana 47405 4401, USA
    Endocrinology 150:4003-11. 2009
  9. pmc Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer
    Meng Li
    Medical Sciences, Indiana University School of Medicine, Bloomington, IN 47405, USA
    BMC Med Genomics 2:34. 2009
  10. pmc Identification and characterization of ovarian cancer-initiating cells from primary human tumors
    Shu Zhang
    Medical Sciences, Indiana University School of Medicine, Bloomington, Indiana 47405, USA
    Cancer Res 68:4311-20. 2008

Collaborators

Detail Information

Publications11

  1. doi Epigenetic targeting therapies to overcome chemotherapy resistance
    Curt Balch
    Medical Sciences, Indiana University School of Medicine, Indiana University School of Medicine, Jordan Hall 300, 1001 East Third Street, Bloomington, IN 47405, USA
    Adv Exp Med Biol 754:285-311. 2013
    ....
  2. pmc A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells
    Curt Balch
    Medical Sciences Program, Indiana University, Bloomington, IN, USA
    Cancer Biol Ther 13:681-93. 2012
    ..These combined computational and experimental approaches may also represent a straightforward means for mechanistic studies of other promising antineoplastics, and/or the identification of agents that may complement epigenetic therapies...
  3. pmc An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules
    Huaxia Qin
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    BMC Syst Biol 3:73. 2009
    ..The regulatory effect of SMAD complex likely depends on transcriptional modules, in which the SMAD binding elements and partner transcription factor binding sites (SMAD modules) are present in specific context...
  4. pmc A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer
    Fang Fang
    Medical Sciences Program, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Cancer 116:4043-53. 2010
    ....
  5. pmc Enriched transcription factor binding sites in hypermethylated gene promoters in drug resistant cancer cells
    Meng Li
    Medical Sciences, School of Medicine, Indiana University, Bloomington, IN 47404, USA
    Bioinformatics 24:1745-8. 2008
    ..In summary, we believe that these.ndings offer a means to further explore the relationship between DNA methylation and gene expression in drug resistance and tumorigenesis...
  6. pmc Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance
    Fuxiao Xin
    School of Informatics, Indiana University, Bloomington, IN 47405, USA
    Bioinformatics 25:430-4. 2009
    ....
  7. doi Methyl group acceptance assay for the determination of global DNA methylation levels
    Kenneth P Nephew
    Department of Cellular and Integrative Physiology, Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN, USA
    Methods Mol Biol 507:35-41. 2009
    ..This assay is applicable to a number of translational and basic research questions...
  8. pmc Minireview: epigenetic changes in ovarian cancer
    Curt Balch
    Medical Sciences, Indiana University School of Medicine, Bloomington, Indiana 47405 4401, USA
    Endocrinology 150:4003-11. 2009
    ..A greater understanding of the role of epigenetics in ovarian neoplasia will provide for improved interventions against this devastating malignancy...
  9. pmc Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer
    Meng Li
    Medical Sciences, Indiana University School of Medicine, Bloomington, IN 47405, USA
    BMC Med Genomics 2:34. 2009
    ..Finally, our results suggest that epigenetic therapies may facilitate the prevention or reversal of transcriptional repression responsible for chemoresistance and the restoration of sensitivity to platinum-based chemotherapeutics...
  10. pmc Identification and characterization of ovarian cancer-initiating cells from primary human tumors
    Shu Zhang
    Medical Sciences, Indiana University School of Medicine, Bloomington, Indiana 47405, USA
    Cancer Res 68:4311-20. 2008
    ..Based on these findings, we assert that epithelial ovarian cancers derive from a subpopulation of CD44(+)CD117(+) cells, thus representing a possible therapeutic target for this devastating disease...
  11. ncbi Epigenetic "bivalently marked" process of cancer stem cell-driven tumorigenesis
    Curt Balch
    Medical Sciences Program, Indiana University, Bloomington, IN, USA
    Bioessays 29:842-5. 2007
    ..These results suggest a possible mechanism by which aberrant differentiation, mediated by histone and DNA methylation, instigates tumor progression...